These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 21474799)
1. Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Mlynash M; Lansberg MG; De Silva DA; Lee J; Christensen S; Straka M; Campbell BC; Bammer R; Olivot JM; Desmond P; Donnan GA; Davis SM; Albers GW; Stroke; 2011 May; 42(5):1270-5. PubMed ID: 21474799 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. Parsons MW; Christensen S; McElduff P; Levi CR; Butcher KS; De Silva DA; Ebinger M; Barber PA; Bladin C; Donnan GA; Davis SM; J Cereb Blood Flow Metab; 2010 Jun; 30(6):1214-25. PubMed ID: 20087363 [TBL] [Abstract][Full Text] [Related]
3. Ischemic Core and Hypoperfusion Volumes Correlate With Infarct Size 24 Hours After Randomization in DEFUSE 3. Rao V; Christensen S; Yennu A; Mlynash M; Zaharchuk G; Heit J; Marks MP; Lansberg MG; Albers GW Stroke; 2019 Mar; 50(3):626-631. PubMed ID: 30727840 [TBL] [Abstract][Full Text] [Related]
4. Early diffusion-weighted imaging and perfusion-weighted imaging lesion volumes forecast final infarct size in DEFUSE 2. Wheeler HM; Mlynash M; Inoue M; Tipirneni A; Liggins J; Zaharchuk G; Straka M; Kemp S; Bammer R; Lansberg MG; Albers GW; Stroke; 2013 Mar; 44(3):681-5. PubMed ID: 23390119 [TBL] [Abstract][Full Text] [Related]
5. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM; Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121 [TBL] [Abstract][Full Text] [Related]
6. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. Inoue M; Mlynash M; Straka M; Lansberg MG; Zaharchuk G; Bammer R; Albers GW Stroke; 2012 Sep; 43(9):2494-6. PubMed ID: 22811464 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Early Reperfusion Criteria in Acute Ischemic Stroke. Ozenne B; Cho TH; Mikkelsen IK; Hermier M; Ribe L; Thomalla G; Pedraza S; Baron JC; Roy P; Berthezène Y; Nighoghossian N; Østergaard L; Maucort-Boulch D J Neuroimaging; 2015; 25(6):952-8. PubMed ID: 25940773 [TBL] [Abstract][Full Text] [Related]
9. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Lansberg MG; Lee J; Christensen S; Straka M; De Silva DA; Mlynash M; Campbell BC; Bammer R; Olivot JM; Desmond P; Davis SM; Donnan GA; Albers GW Stroke; 2011 Jun; 42(6):1608-14. PubMed ID: 21493916 [TBL] [Abstract][Full Text] [Related]
10. Use of Diffusion-Weighted Imaging-Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) and Ischemic Core Volume to Determine the Malignant Profile in Acute Stroke. Yoshimoto T; Inoue M; Yamagami H; Fujita K; Tanaka K; Ando D; Sonoda K; Kamogawa N; Koga M; Ihara M; Toyoda K J Am Heart Assoc; 2019 Nov; 8(22):e012558. PubMed ID: 31698986 [TBL] [Abstract][Full Text] [Related]